Core Viewpoint - The company, Sihuan Pharmaceutical (00460), has announced a positive earnings forecast, expecting revenue of at least 2.5 billion RMB for the year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1][5]. Group 1: Financial Performance - The company anticipates a net profit of no less than 150 million RMB for the same period [1][5]. - The growth in performance is primarily driven by the rapid expansion of the medical aesthetics business, which is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1][5]. Group 2: Business Segments - The medical aesthetics segment has become the largest contributor to both revenue and profit for the company, significantly boosting overall performance [1][5]. - The innovative drug business is entering a harvest phase, which is expected to improve the company's profit structure [1][5]. Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having conducted multiple rounds of share buybacks and completed the spin-off of Xuan Bamboo Biotechnology, which has optimized the financial structure and driven profit breakthroughs [1][5].
四环医药盘中涨超6% 预期全年收入同比增速超30%